(Le Quoc-Viet) - Seoul National University College of Pharmacy
(Choi Jin-Joo) - Seoul National University College of Pharmacy
¿ÀÀ¯°æ(Oh Yu-Kyoung) - Seoul National University College of Pharmacy
Abstract
Cancer immunotherapy takes advantage of immune system to fight against cancer. Current clinical immunotherapies are based on the administration of immune checkpoint inhibitors or immune modulators to reverse the immune suppression. Although robust and long-term tumor suppression is induced in ¡°certain treated population¡±, single immunotherapy still suffers from limited efficacy in clinic. Combination with nanomedicine would be one of major strategies that can widen the effective patient populations and reduce side effects. The basis in combining nanomedicine and immunotherapy stems from the close relationship of tumor and immune system. Depending on the therapeutic cargo, nanocarriers can not only facilitate stronger innate or adaptive immunity but also reverse of immunosuppression. In the other hand, nanotechnology can potentiate the efficacy of immunotherapy by enhancing the delivery, retention and narrow the toxicity of immunomodulators. The strategies and rationales of nanocarrier design in the context of cancer immunotherapy are discussed in this review.
Å°¿öµå
Nanomedicine, Immunotherapy, Immune checkpoint inhibitor, Cancer, Combination
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
In most studies, in vivo studies have been done with a single set of combination in comparison with the nanocarrier entrapping each drug alone.